NCT06552000
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
StatusWithdrawn
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Withdrawn before enrolling Sponsor's reason: Sponsor deprioritized the study and made the choice to close the study. Show 5 more changesShow less
- Enrollment target: estimated 18 to confirmed 0
- Start date: Jul 1, 2026 to Oct 1, 2026
- Eligibility criteria expanded, about 16 words
- Secondary endpoints: details revised at 1 of 1 entry
- Site contact updated
- Notable Primary completion date: Dec 1, 2027 to Dec 1, 2029
- Start date: Dec 1, 2025 to Jul 1, 2026
- Study completion date: Dec 1, 2029 to Dec 1, 2030
- Notable Start date: Sep 1, 2025 to Dec 1, 2025v5
- Notable Start date: May 31, 2025 to Sep 1, 2025v4
- Notable Start date: Feb 28, 2025 to May 31, 2025v3
- Notable Start date: Dec 1, 2024 to Feb 28, 2025v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes.
Timeframe: approximately 14-28 days
Secondary (1)
Safety of administering TTFields
Arms and interventions
Tumor Treatment FieldsExperimental
Duration: 2-4 week; target 18 hours/day (on average). Continuous between time of enrollment and date of surgery. Cycle Length: 2-4 weeks
Devices: NovoTTF-200T System
Sites
1 site in 1 country
- The University of Texas Southwestern Medical CenterDallas, Texas, United States